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ligands presently considered for possible human use, only 3,4,3-LI(1,2-HOPO) removed potentially useful amounts of both Pu and Am from bone mineral.
INTRODUCTION
One issue in decorporation therapy that has remained intractable to solution is the removal of actinides such as Pu and Am once they have become bound to mineralized bone (1) . This unfortunate circumstance means that individuals with systemic burdens of Pu and/or Am would incur a risk of dose-dependent bone cancer for which the only dose and risk reduction possible would be interception of actinide released by structural skeletal remodeling. In vitro studies with bone mineral surrogates show that binding of Pu and Am occurs relatively rapidly (< 8 h), is tenacious, and Pu is not amenable to removal by the chelating agent of choice today, DTPA (diethylenetriaminepentaacetic acid), whether in Ca or Zn chelate forms (2) . Chelating agents that can remove Pu and/or Am from bone surfaces would be valuable. This study was undertaken to test a set of ligands that were designed to bind actinides with great specificity and stability. All of these ligands, with their different backbones, denticities and functional groups, have been tested primarily in mice for efficacy in decorporating intravenously injected Pu (3) (4) (5) (6) (7) (8) and some have been tested for in vivo chelation of Am (9) (10) (11) (12) (13) . Using a previously described in vitro system in which Pu or Am were allowed to bind to a crystalline bone mineral surrogate, calcium hydroxyapatite (2) (HAP), a test ligand was added at various concentrations, and its ability to solubilize the HAP-bound Pu or Am was determined as functions of concentration and incubation time. Because the chemistry of actinide binding to bone mineral has yet to be elucidated, it was not reasonable to predict which compounds would be more or less effective; nevertheless, the structural features encompassed by this set of compounds were expected to influence their binding affinities for the actinides. This was borne out experimentally.
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Materials
Solutions of 238 Pu(IV) and 241 Am(III) in 0.005M citrate were prepared as before using stock materials available in the Institute (2) . The pH was adjusted to 7.0 " 0.1 by gradual addition of NaOH. The 10 test ligands containing two, three or four catecholate, hydroxypyridinonate, or hydroxamate functional groups attached to suitable molecular backbones are listed in Tables 1   and 2 . They were prepared at the University of California, Berkeley, Department of Chemistry (UCB) using published methods (3, 4, 6, 7) . ZnNa 3 DTPA, HAP, HEPES buffer and other chemicals were purchased from commercial sources.
Methods
The techniques used have been described (2) . Briefly, Pu(IV) or Am(III) citrate (3.7 kBq per sample) was added to stirred covered beakers containing 10 mg per sample of the bone mineral surrogate HAP that had been equilibrated for 24 hours in 0.1 M HEPES buffer. The pH was adjusted to 7.2 "0.01 before addition of the actinide. After allowing the actinide to bind to HAP for 24 h, a chelating agent was added to pairs of samples at concentrations of 1, 10 or 100
:M and incubated at room temperature in the continuously stirred containers for 1, 2, 4, 8, 24 or 48 h. Unbound Pu and Am, taken to indicate complexed actinide removed from bone, was measured by ultrafiltration (Amicon Centriflo CF25 ultrafiltration cones; MW cutoff 25kd) and alpha-liquid scintillation (LS) counting of the ultrafiltrate. HEPES blanks and Pu-or Am-spiked standards were used to account for any changes in the LS counting conditions.
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The results are summarized in Table 1 for Pu and Table 2 for Am. All data are expressed as the fraction of unbound actinide, i.e., ultrafilterable through the 25-kd ultrafiltration cones. As a point of reference, Guilmette et al. (2) had determined that 0.02-0.04% of Pu and about 0.05% of Am is present in the ultrafiltrate and can be considered to be unbound at 24 h incubation, in the absence of chelating agents. These appear to be equilibrium concentrations of actinide in suspensions of HAP, and can be compared with the values in Tables 1 and 2 The bone mineral surrogate, HAP, used in this study, is a finely divided crystalline solid with the composition, crystal structure, and surface area of native bone mineral. (2, 15) In aqueous suspension, these small polarizable particles acquire a layer of bound water, the "hydration shell", due to the strong electric field of unsatisfied charges on their surfaces. The apparently irreversible binding of Pu and Am to these crystal surfaces, in all likelihood, involves displacement of surface Ca and bonding of the actinides by spatially available phosphate(s) (15) .
In order to disrupt that bonding, an incoming ligand must be sufficiently hydrophilic to penetrate the hydration shell, and the stabilities of its Pu and/or Am complexes must appreciably exceed those of the actinide phosphate complexes formed on the mineral surfaces.
The varied designs of the test ligands provide a matrix for examining the influences of molecular structure (denticity and backbone configuration) and coordination properties of the functional groups on the abilities of the ligands to compete for Pu and/or Am bound to the HAP surfaces. Competition for Pu and/or Am will be discussed separately.
Removal of Pu: ligand structure. For Pu removal, denticity, that is, the number of available binding sites per ligand molecule, is the most important structural feature, regardless of the specific backbone configuration. Ligand effectiveness for Pu removal was, in decreasing order: octadentate > hexadentate > tetradentate, and the five effective ligands are structurally octadentate. Removal of Pu from bone mineral by those octadentate ligands is shown in Table 3 in the order of their decreasing effectiveness, based on 100 :M ligand concentration and 24-48 h incubation.
The backbones of four of the effective ligands are linear spermine (3,4,3-LI) and The best estimates of the formation constants (log K) for the 1:1 Pu(IV) complexes formed at pH 7.2 with the effective octadentate ligands are given in Table 3 Table 3 ). These five ligands or their structural analogues are rapidly excreted, (22) (24) and presumably that is also the case for the similar Am(III) ion.
It is likely that the tetradentate HOPO ligands form one-to-one, unsaturated Am(III) complexes. 
Three of the test ligands contain functional groups that are not suitable for stable Am(III) complexation at pH 7.2, the catecholates, CAM(S) and CAM(C), and hydroxamate (as in DFO-
(1,2-HOPO)). The efficacies of the octadentate ligands containing those functional groups were 13 poor for reducing retention of Am in the skeletons of rodents or dogs. (9, 11, 25, 26) Unlike the HOPO functional groups, which are ionized and ready for metal binding at physiological pH, the -OH groups of catechol and hydroxamate must be deprotonated before they can bind metal ions. (4, 20) Those functional groups form stable complexes with small ions like Fe(III) and Pu(IV) at pH 7 to 8, (6, 20) but Am(III) with its lesser charge/radius ratio does not deprotonate a sufficient number of catecholate or hydroxamate functional groups to form stable Am(III) complexes in that pH range. Although Am(III) deprotonates and binds with only three of the eight available -OH groups of 3,4,3-LICAM(C) at pH 7.2 (6, 14) that ligand removed about 6% of mineral-bound Am in 24 to 48 h (100 :M); possibly, as had been suggested, because the free carboxyls, which were added to the catechol rings of that ligand to increase its aqueous solubility, are participating in Am binding.
Comments. This in vitro model shows that several of the test ligands are appreciably more effective for removal of Pu and/or Am from bone mineral than ZnNa 3 DTPA, and it provides a rational chemical basis for their effectiveness or lack thereof. Several important structural features determine whether a ligand will be effective for removing an actinide from bone mineral: appropriate denticity, a suitable molecular backbone, good aqueous solubility at physiological pH, and most importantly, functional groups that form stable actinide complexes at reasonably fast rates in the physiological pH range.
It is also clear that this study represents only one aspect of the assessment of a ligand that can target and remove an actinide deposited in bone. The ability to achieve and maintain adequate local concentrations near bone surfaces in the face of rapid ligand excretion, which is characteristic of many of these hydrophilic ligands, (22) requires further study.
14 Ligand toxicity must also be considered. Among the eight most effective ligands for Pu and/or Am removal, three have serious toxicity-related problems at effective dosage in vivo:
3,4,3-LICAM(S) is toxic in the dog kidney, (9) 3,4,3-LICAM(C) leaves potentially toxic Pu and
Am residues in rodent kidneys, (6, 26) and H(2,2)-(Me-3,2-HOPO) is severely renally toxic in mice. (8) The five ligands of low to moderate toxicity at effective in vivo dosage include: DFO-(1,2-HOPO) (4) (effective only for Pu removal from bone mineral), TREN-(Me-3,2-HOPO), TREN-(1,2-HOPO) and 5-LIO(Me-3,2-HOPO) (8) (all effective only for Am removal), and 3,4,3-LI(1,2-HOPO), which stands out as the only test ligand with acceptably low toxicity in in vivo assessments to date (8, 12, 22) that removed both Pu and Am from bone mineral. b Ligand denticities: O, octadentate (4, 5, 7, 8) : O-H, structurally octadentate, but functionally hexadentate at pH 7.2 (6, 14) ; H, hexadentate (8, 10) ; T, tetradentate (8) 18
Fraction Unbound Am (%) b Ligand denticities: O, octadentate (4, 5, 7, 8) : O-T, structurally octadentate, but functionally tri-or tetradentate for binding Am(III) at pH7.2 (6, 14) ; H, hexadentate (8, 10) ; T, tetradentate (7, 8) 238 Pu citrate, and killed at 24 h. (5, 8) d Based on speciation calculations and analogy to hexadentate catecholate complexes of Eu(III). (6, 14) e Based on measurement of logK (25°C, I=0.1) for Th(IV)-(1,2-HOPO) 4 , adjusted for smaller size of Pu(IV) ion. 
g Based on measurement of logK (25°C, I=0.1) of Th(IV)-DFO-(1,2-HOPO), adjusted for smaller size of Pu(IV) ion. (18) 
